The race to treat a number of health conditions using neurostimulation technology is a marathon, not a sprint—but Medtronic and Axonics Modulation Technologies are still aiming for a photo finish. For ...

In 2020, hot on the heels of Axonics Modulation Technologies’ FDA approval for a rechargeable neuromodulation implant to treat urinary and bowel dysfunction, Medtronic scored a regulatory win of its ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...

Wall Street doesn't typically embrace med-tech IPOs for companies without at least one product on the market that's generating significant revenues. But even in a volatile stock market, it's made an ...

Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value ...

KRAS-mutated tumors were once untreatable. In fact, KRAS was something of a poster child for so-called undruggability. Several laboratories are investigating ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

An Axonics sacral neuromodulation system sends electrical signals to nerves in the spinal cord to help regulate the bladder and bowels Device maker Axonics Inc. says its newest system designed to ...